Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Serial Procalcitonin Measurements Utilized in Hospitalized Community-Acquired Pneumonia

By LabMedica International staff writers
Posted on 19 Mar 2020
Community-acquired pneumonia (CAP) refers to pneumonia (any of several lung diseases) contracted by a person with little contact with the healthcare system. More...
CAP, the most common type of pneumonia, is a leading cause of illness and death worldwide. Its causes include bacteria, viruses, fungi and parasites.

To improve the prognosis of CAP patients, assessment of its severity is important for selecting appropriate antimicrobial agents and site of treatment, whether as an outpatient or in hospital, including a general ward or intensive care unit (ICU). Either CURB-65 or the Pneumonia Severity Index (PSI) is often used to assess the severity of pneumonia because they have been validated to correlate well with prognosis.

Scientists at the Kurashiki Central Hospital (Okayama, Japan) investigated the usefulness of serial procalcitonin (PCT) measurements for predicting the prognosis and treatment efficacy for hospitalized CAP patients. This prospective, multicenter, cohort study enrolled consecutive CAP patients who were hospitalized at 10 hospitals in western Japan from September 2013 to September 2016.

Sputum and blood for cultures and blood for measuring serum antibodies were collected on admission to detect the causative pathogens of CAP. In all hospitals, the serum PCT levels were measured by the Elecsys BRAHMS PCT automated immunoassay (Roche Diagnostics GmbH, Mannheim, Germany), which had a detection limit of 0.02 ng/mL.

The investigators reported that in the 710 patients, 366 microorganisms were identified. The most common causative microorganism was Streptococcus pneumoniae (22.2%), followed by Haemophilus influenzae (11.1%). Both PCT and CRP values on day 1 (D1), D3, and D7 were significantly higher in non-survivors than in survivors. From D1 to D3, the non-survivor group showed increased PCT (PCT D3/D1 > 1) more often than the survivor group, whereas the increase of CRP (CRP D3/D1 >1) was not significantly different. Compared with patients with treatment success, patients with early treatment failure showed significantly higher values of PCT D1, D3, and CRP D3, but similar CRP D1 values.

The authors concluded that to assess prognosis and treatment efficacy in CAP, it would be ideal to measure PCT serially, not only on admission, but again on day 3. If the values of PCT increase from admission to day 3, the antibiotics may need to be changed, or the patients who have deteriorated may require close monitoring. The study was published on March 1, 2020 in the International Journal of Infectious Diseases.

Related Links:
Kurashiki Central Hospital
Roche Diagnostics GmbH



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.